- Home
- ATOS vs OFS Comparison
ATOS vs OFS Comparison
Compare ATOS & OFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATOS
- OFS
- Stock Information
- Founded
- ATOS 2009
- OFS 2001
- Country
- ATOS United States
- OFS United States
- Employees
- ATOS 10
- OFS N/A
- Industry
- ATOS Biotechnology: Pharmaceutical Preparations
- OFS Finance/Investors Services
- Sector
- ATOS Health Care
- OFS Finance
- Exchange
- ATOS Nasdaq
- OFS Nasdaq
- Market Cap
- ATOS 114.5M
- OFS 107.9M
- IPO Year
- ATOS 2012
- OFS 2012
- Fundamental
- Price
- ATOS $0.96
- OFS $8.08
- Analyst Decision
- ATOS Strong Buy
- OFS
- Analyst Count
- ATOS 3
- OFS 0
- Target Price
- ATOS $7.00
- OFS N/A
- AVG Volume (30 Days)
- ATOS 826.7K
- OFS 62.6K
- Earning Date
- ATOS 11-12-2024
- OFS 03-03-2025
- Dividend Yield
- ATOS N/A
- OFS 16.83%
- EPS Growth
- ATOS N/A
- OFS N/A
- EPS
- ATOS N/A
- OFS N/A
- Revenue
- ATOS N/A
- OFS $49,799,000.00
- Revenue This Year
- ATOS N/A
- OFS N/A
- Revenue Next Year
- ATOS N/A
- OFS N/A
- P/E Ratio
- ATOS N/A
- OFS N/A
- Revenue Growth
- ATOS N/A
- OFS N/A
- 52 Week Low
- ATOS $0.77
- OFS $7.75
- 52 Week High
- ATOS $2.31
- OFS $12.07
- Technical
- Relative Strength Index (RSI)
- ATOS 39.54
- OFS 47.46
- Support Level
- ATOS $0.81
- OFS $8.00
- Resistance Level
- ATOS $0.94
- OFS $8.15
- Average True Range (ATR)
- ATOS 0.05
- OFS 0.14
- MACD
- ATOS 0.01
- OFS 0.01
- Stochastic Oscillator
- ATOS 39.13
- OFS 56.67
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary innovative medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.
About OFS OFS Capital Corporation
OFS Capital Corp is an externally managed, closed-end, non-diversified management investment company. Its business objective is to generate current income and capital appreciation by investing in middle-market companies in the United States. The company focuses on investments in senior secured loans, including first lien, second lien, and unitranche loans, as well as subordinated loans and, to a lesser extent, warrants, and other equity securities.